Pralatrexate Completed Phase 3 Trials for Refractory Peripheral T-Cell Lymphoma / Cutaneous T-Cell Lymphoma Recurrent Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03349333A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL